Hi, welcome back!

If you like the post Share it!

BullsInvest.com is not checking the facts behind the Guest Posts of its users.

150

Follower

140

Place Stay

45

Reviews
Our Latest News
ARK Innovation ETF (Cathie Wood )Is Selling Off — and It May Get Worse
ARK Innovation ETF (Cathie Wood )Is Selling Off — and It May Get Worse

One of the hottest exchange-traded funds is sliding again, and the selloff may only get worse.

Dogecoin surges 55% as fans try to push it to $1
Dogecoin surges 55% as fans try to push it to $1

Dogecoin (DOGE-USD) has nearly doubled in value since April, rising over 50% after another surge driven by internet users who are trying to push the coin to $1, as similar plans for "Doge Day" fell flat last month.

Cocrystal Pharma stock doubles on massive volume shortly after progress on coronavirus drug candidates
Cocrystal Pharma stock doubles on massive volume shortly after progress on coronavirus drug candidates

Shares of Cocrystal Pharma Inc. COCP, +72.58% more than doubled on massive record volume in afternoon trading

1000 USD bet on Dogecoin for Christmas now tops the average US Income
1000 USD bet on Dogecoin for Christmas now tops the average US Income

It took Amazon 13 years to deliver a 10,000% return to investors. It has now taken Dogecoin five months. The cryptocurrency (DOGE-USD) hit a new all-time high of $0.60 on Tuesday, pushing Dogecoin's market cap north of $70 billion to become the fourth-most valued coin, according to Yahoo Finance's data partner CoinMarketCap. That's now larger than the market cap of Moderna, one of the companies shipping COVID-19 vaccines to save the world from the pandemic.

Cocrystal Pharma stock doubles on massive volume shortly after progress on coronavirus drug candidates

Shares of Cocrystal Pharma Inc. COCP, +72.58% more than doubled on massive record volume in afternoon trading


Tuesday, a day after the biotechnology company said it has made "progress" in developing antiviral drug candidates that target coronaviruses, including those that cause COVID-19.

Trading volume skyrocketed to 559.5 million shares, compared with the full-day average of about 832,300 shares. Cocrystal launched its COVID-19 program in March 2020. The stock's previous record for trading volume was 81.1 million shares on Feb. 24, 2020. "We are aggressively developing novel coronavirus protease inhibitors for COVID-19 prophylactic and therapeutic use," said President Sam Lee, in Monday release.

"Our high-resolution x-ray cocrystal structures further confirmed the specific covalent interaction with this conserved region of the proteases of the coronaviruses SARS-CoV-2, SARS-CoV and MERS-CoV viruses." The stock, which was recently up 104.0%, has now run up 86.0% year to date, while the iShares Nasdaq Biotechnology ETF IBB, -2.84% has slipped 1.2% and the S&P 500 SPX, -0.67% has gained 10.5%.


Leave a Reply